financetom
Business
financetom
/
Business
/
UBS Raises Its Eurozone GDP Growth Forecasts Slightly This Year, Lowers for 2025
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS Raises Its Eurozone GDP Growth Forecasts Slightly This Year, Lowers for 2025
Oct 7, 2024 5:42 AM

08:26 AM EDT, 10/07/2024 (MT Newswires) -- UBS said it raised its eurozone gross domestic product growth forecast by 0.1pp to 0.7% for this year while the consensus is for 0.7%, given stronger-than-expected growth in H1 2024.

At the same time, the bank cut its 2025 GDP forecast by 0.3pp to 0.9% while the consensus is for 1.3%, given a weaker outlook for eurozone growth in H2 2024 and H12025.

Growth indicators have been mixed and uneven across eurozone countries and sectors in recent months, but lately, a broader loss of momentum has been evident as manufacturing continues to slow amid a weak external environment and services appear to lose steam too, stated UBS.

The bank believes this warrants a more cautious view on economic activity over the coming quarters and also means that the European Central Bank will lower interest rates faster than UBS assumed until recently -- it now estimates a cut in October and accelerated cuts in early 2025.

Crucially, UBS isn't turning outright pessimistic on eurozone growth -- it isn't calling for a recession. After all, UBS forecasts labor markets to remain relatively resilient, so stabilizing growth, but also preventing wage growth and services inflation from coming down quickly.

However, should European labor markets "break", with unemployment going up a lot, growth would likely be much weaker, wage growth and inflation lower, and the ECB would gain scope to cut rates more significantly than the bank's baseline assumes.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Huntington Bancshares to Acquire Veritex for $1.9 Billion
Huntington Bancshares to Acquire Veritex for $1.9 Billion
Jul 14, 2025
08:30 AM EDT, 07/14/2025 (MT Newswires) -- Huntington Bancshares ( HBAN ) has entered into an agreement to acquire Veritex ( VBTX ) in an all-stock deal valued at $1.9 billion, the companies said Monday. Under the terms of the deal, Huntington will issue 1.95 shares for each outstanding share of Veritex ( VBTX ). The consideration implies $33.91 per...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Avalon GloboCare Receives Hong Kong Patent for Advanced CAR-T, CAR-NK Cell Technology
Avalon GloboCare Receives Hong Kong Patent for Advanced CAR-T, CAR-NK Cell Technology
Jul 14, 2025
08:32 AM EDT, 07/14/2025 (MT Newswires) -- Avalon GloboCare ( ALBT ) said Monday it granted a new standard patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer cell technology. The company said the patent for the technology, co-developed with Hong Kong-based partner Arbele, is valid for 20 years, starting Feb. 21, 2020. The patented technology would boost...
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer
Jul 14, 2025
08:30 AM EDT, 07/14/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday that it has filed a New Drug Application with the US Food and Drug Administration for its selective cortisol modulator relacorilant to treat patients with platinum-resistant ovarian cancer. The filing is based on the results of the treatment's pivotal late-stage and mid-stage trials, which showed that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved